Niemann Capital Management’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Niemann Capital Management’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-47,715	Closed	-$2.06M	–	10
2020 Q2	$2.06M	Buy	47,715 +9,487	+25%	+$363K	2.67%	4
2020 Q1	$1.12M	Buy	+38,228	New	+$1.32M	1.19%	4
2018 Q3	–	Sell	-507,231	Closed	-$16.6M	–	14
2018 Q2	$16.6M	Sell	507,231 -1,108	-0.2%	-$36.4K	9.62%	7
2018 Q1	$16.7M	Buy	+508,339	New	+$16.6M	10.83%	5

Other funds holding BBC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

FEM

Fulcrum Equity Management Plano, Texas $136M AUM 42.95% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Niemann Capital Management's BBC Position: Q3 2020 in Review

Niemann Capital Management sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q3 2020, closing a stake of 47,715 shares — an estimated $2.06M sold.

Niemann Capital Management first reported a position in BBC in Q1 2018 and held it in 4 quarters. The position peaked at $16.7M in Q1 2018. 18 funds tracked by Wall St. Rank hold BBC as of Q3 2020.

Niemann Capital Management reported no remaining Virtus Biotech Clinical Trials ETF position as of Q3 2020 after selling out during the quarter.
Niemann Capital Management sold 47,715 Virtus Biotech Clinical Trials ETF shares in Q3 2020, an estimated $2.06M.
Niemann Capital Management first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2018 and held it in 4 quarters.
Niemann Capital Management's Virtus Biotech Clinical Trials ETF position peaked at $16.7M in Q1 2018.
18 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q3 2020.

Based on Niemann Capital Management's 13F filing for Q3 2020, filed 10 Nov 2020.